Han S. Lee

Dr. Han S. Lee

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Toxins
Verified
Journal Article
Open access
PDF file
KDKhashayar Dashtipour
Khashayar Dashtipour
HLHan S. Lee
Han S. Lee
AEAaron Ellenbogen
Aaron Ellenbogen
RKRashid Kazerooni
Rashid Kazerooni
TGTodd Gross
Todd Gross
CGConor J Gallagher
Conor J Gallagher
The first-line management of cervical dystonia (CD) symptoms is intramuscular injection of botulinum toxin type A (BoNTA). However, a comparison of safety among BoNTAs is difficult because, per regulatory authorities, units of BoNTA activity are not interchangeable. Dysphagia and muscle weakness are widely considered two key adverse events to monitor closely in the treatment of CD. This integrated analysis compared the safety of BoNTAs approved for CD in the US by evaluating relationships between the incidence of dysphagia and muscle weakness in prescribing information and the core neurotoxin content. Coefficients The coefficients of determination (R2) and trendlines were estimated via regression-based lines of best fit. Adverse drug reaction (ADR) rates were strongly correlated with core neurotoxin amounts for conventional BoNTAs (slope coefficients: dysphagia = 0.048, R2 = 0.74; muscle weakness = 0.096, R2 = 0.82). The published ADR rates at approved doses for conventional BoNTAs were higher compared with DaxibotulinumtoxinA (DAXI; DAXXIFY®, Revance Therapeutics, Inc., Nashville, TN, USA) by core neurotoxin content. The use of a core neurotoxin amount was found to be an effective method for comparing the safety of BoNTA products. Current clinical trials suggest that DAXI, a novel BoNTA formulation, provides a potentially wider safety margin compared with other approved BoNTAs for CD. The lower amount of core neurotoxin administered at approved doses compared with conventional BoNTAs may explain low on-target ADRs like muscle weakness, whereas reduced diffusion from the injection site is thought to be responsible for low off-target ADRs like dysphagia.

3 February 2026 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
LBLaxman Bahroo
Laxman Bahroo
AEAaron Ellenbogen
Aaron Ellenbogen
RHRobert Hauser
Robert Hauser
HLHan S. Lee
Han S. Lee
PMPeter McAllister
Peter McAllister
DHDavid A. Hollander
David A. Hollander
Background: DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials. Objective: To report findings from PrevU, an early experience, real‐world observational program initiated following DAXI's FDA approval. Methods: Movement disorder specialists were provided with DAXI to treat CD patients per routine clinical practice, and were surveyed on dosing patterns and treatment intervals across the first three cycles of DAXI as doses were optimized. Results: A total of 234 CD patients (206 receiving BoNT treatment and 28 BoNT‐naïve) received a total of 589 DAXI treatments. Among patients with prior BoNT therapy, breakthrough symptoms within 12 weeks of prior BoNT therapy was the most common reason for patient selection (76.2%), and onabotulinumtoxinA was the most common prior toxin (68.4%). DAXI dose was titrated from a mean of 244.4 U (median 250 U) to 314.7 U (median 300 U) by Cycle 3. The ratio of DAXI dose to normalized prior BoNT dose was approximately 1.1:1 at initiation and 1.4:1 at Cycle 3. The mean (SD) time to re‐treatment across all DAXI cycles was 16.1 (5.6) weeks for all patients and 15.7 (4.5) weeks for patients with a history of breakthrough before 12 weeks with prior toxin. The most common adverse events were muscle weakness (2.4% of treatments), injection pain (1.4% of treatments), and dysphagia (0.3% of treatments). Conclusions: In this real‐world setting, DAXI demonstrated extended clinical benefit and a favorable safety profile.

26 October 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
LBLaxman Bahroo
Laxman Bahroo
KDKhashayar Dashtipour
Khashayar Dashtipour
AEAaron Ellenbogen
Aaron Ellenbogen
JFJill G. Farmer
Jill G. Farmer
RHRobert Hauser
Robert Hauser
CGConor J. Gallagher
Conor J. Gallagher